Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Allowed: EGFR any tested

Actionable gene alterations are eligible if failed targeted therapeutic options.

Must have received: chemotherapy — standard of care

progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination)

Must have received: anti-PD-1 therapy — standard of care

progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination)

Must have received: platinum-based chemotherapy — recurrent or metastatic

progressed on platinum and PD-1/PD-LI in recurrent or metastatic setting

Must have received: anti-PD-1 therapy — recurrent or metastatic

progressed on platinum and PD-1/PD-LI in recurrent or metastatic setting

Must have received: oxaliplatin

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: irinotecan

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: antimetabolite (fluoropyrimidine)

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: EGFR inhibitor

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: VEGF inhibitor

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: VEGFR inhibitor

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: TAS-102

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: regorafenib

Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib

Must have received: cytotoxic chemotherapy

progressed on at least 1 prior cytotoxic chemotherapeutic regimen

Must have received: immune checkpoint inhibitor

if applicable immune checkpoint inhibitor

Must have received: HER2-targeted therapy

if applicable ... HER2 therapy

Must have received: platinum-based chemotherapy

post SOC ... Platinum resistant cannot have >5 lines of prior therapy

Must have received: chemotherapy

progressed after SOC

Must have received: taxane

Progressed after >1 systemic therapy that must have included taxane

Cannot have received: immunotherapy targeting T-cell co-stimulation

treatment naïve to immunotherapy targeting T-cell co-stimulation

Cannot have received: anticancer therapy

anticancer therapy within 5 half-live or 28 days (whichever is shorter)

Cannot have received: agent targeting Chemokine Receptor (CCR)8

agent targeting Chemokine Receptor (CCR)8